Our Speakers

Dr Toh Han Chong is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at Duke NUS Medical School. He completed his International Baccalaureate on a United World College scholarship to Lester Pearson College, British Columbia, Canada. Dr Toh then obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and his medical degree from the University of Cambridge, UK. His oncology and translational research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the Singhealth Duke NUS Cell Therapy Centre. Dr Toh received the National Senior Clinician Scientist Award in 2017, National Medical Excellence Award (NMEA) in 2018 and the NMRC STaR Award in 2022. Dr Toh is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS).

 

He is European Society for Medical Oncology (ESMO) Scientific Faculty for Cancer Immunology & Immunotherapy and chair of Investigational Immunotherapy at ESMO Annual Congress 2026 in Madrid, Spain. Dr Toh has published over 160 peer review journal papers. He is co-founder of NeoTILa Pte Ltd.

Prof Toh Han Chong's Session:

• Innovation Plenary
  Date: 19 Sep 2025, Friday | Time: 1120—1205 | Venue: The NAK Auditorium